+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Fetal Bovine Serum Market by Application, End User: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 189 Pages
  • November 2021
  • Region: Global
  • Allied Market Research
  • ID: 5533747
The global fetal bovine serum was valued at $796.25 million in 2020, and is projected to reach $1,375.53 million by 2030, registering a CAGR of 5.4% from 2021 to 2030.

Fetal bovine serum (FBS) is considered as an ideal medium growth supplement and is usually preferred over other types of animal sera. The high levels of nutrients and optimal combination of growth factors offered by makes it a suitable growth supplement for cell cultures. Further, the significantly lower content of antibodies compared to adult and newborn sera minimizes the risk of antibody cross reaction with cells in culture.

FBS finds its application for several research purposes including cancer research, development of biopharmaceuticals, and other research purposes. In addition, sera are widely used as additional growth supplements along with culture media preparation made precisely for growth, storage, maintenance, and transport of microorganisms and different types of cells. The array of various media available in research allows culturing of cell types and microorganisms. Quality of FBS is determined mainly for blood collection site and raw serum processing center. Appropriate collection is fundamental to maintaining natural growth-promoting properties of fetal blood, thus achieving consistent and superior performance of the final Fetal Bovine Serum products.

Rise in research and development regarding the development of biopharmaceuticals has fueled led to growth of the fetal bovine serum industries. In addition, the constant expansion of biopharmaceutical research is anticipated to create surge rise in the demand for production and supply chain of the FBS market in the future. Moreover, increase in investments and funding for research interventions in both developed and developing countries drives the market growth. However, animal welfare and ethical & scientific concerns associated with the use of fetal bovine restrict the fetal bovine serum market growth. However, untapped potential of the emerging markets is anticipated to provide lucrative opportunities to key players involved in the fetal bovine serum market.

Based on fetal bovine serum market analysis by application, the market is categorized in to biopharmaceuticals, human and animal vaccine, and others. The biopharmaceuticals segment was the highest contributor to the market in 2020 and is anticipated to maintain its dominance throughout the forecast period.

Based on region, the global fetal bovine serum market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market in 2020, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. This is attributed to increased funding by government agencies and rise in focus to develop biopharmaceuticals in this region. However, as per the fetal bovine serum market forecast, Asia-Pacific is projected to register highest growth rate from 2021 to 2030.

The report provides a comprehensive analysis of the leading companies operating in the global market such as Danaher (Cytiva), Merck KGaA (Sigma Aldrich), HiMedia Laboratories Pvt., Ltd, Bio-Techne, Sera Scandia (Biowest), Sartorius (Biological Industries), Atlas Biologicals, Rocky Mountain Biologicals, PAN-Biotech and Thermo Fisher Scientific Inc. Other players in the value chain (not included in the report) include Takara Bio, Inc., Tissue Culture Biologicals, Caisson Laboratories, Inc., Cell Culture Technologies LLC and Biomol GmbH and Nucleus Biologics.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of four regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global fetal bovine serum market.

KEY MARKET SEGMENTS


By application

  • Biopharmaceuticals
  • Human and Animal Vaccines
  • Others (IVF and IVD)

By End User

  • Biotechnology & Pharmaceutical Industries
  • Academic Institutes
  • Others (Research labs, Diagnostic labs, CRO, CMO and IVF centers)

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Danaher (Cytiva)
  • Merck KGaA (Sigma Aldrich)
  • HiMedia Laboratories Pvt. Ltd
  • Bio-Techne
  • Sera Scandia (Biowest)
  • Sartorius (Biological Industries)
  • Atlas Biologicals
  • Rocky Mountain Biologicals
  • PAN-Biotech
  • Thermo Fisher Scientific Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)

  • Takara Bio, Inc.
  • Tissue Culture Biologicals
  • Caisson Laboratories, Inc.
  • Cell Culture Technologies LLC
  • Biomol GmbH and Nucleus Biologics.

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.3. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key Forces Shaping Fetal Bovine Serum Industries/Market
3.2.1. Moderate bargaining power of suppliers
3.2.2. Low bargaining power of buyers
3.2.3. Low threat of substitutes
3.2.4. Low intensity of rivalry
3.2.5. Moderate Threat of Substitution
3.4. Market evolution/Industries roadmap
3.5. Value Chain Analysis
3.6. Impact of government regulations on global fetal bovine serum market
3.7. Industries Pain point analysis
3.8. Key findings
3.8.1. Top impacting factors
3.8.2. Top investment pockets
3.8.3. TOP PLAYER POSITIONING, 2020
3.9. Case Studies
3.9.1. Case Study 01
3.10. Market dynamics
3.10.1. Drivers
3.10.1.1. Rise in R&D investments
3.10.1.2. High demand for fetal bovine sera
3.10.1.3. Surge in biopharmaceutical production
3.10.2. Restraints
3.10.2.1. Ethical and scientific issues associated with collection of fetal bovine serum
3.10.2.2. Increase in use of alternatives
3.10.3. Opportunity
3.10.3.1. Untapped potential of emerging economies
3.10.4. COVID-19 Impact analysis
CHAPTER 4: FETAL BOVINE SERUM MARKET, BY APPLICATION
4.1. Overview
4.1.1. Market size and forecast, by application
4.2. Biopharmaceuticals
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Human & Animal Vaccine
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Others
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
CHAPTER 5: FETAL BOVINE SERUM MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast, by end user
5.2. Biotechnology & Pharmaceutical Industries
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Academic Institutes
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Others
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: FETAL BOVINE SERUM MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast, by region
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. Market analysis, by country
6.2.3. Market size and forecast, by application
6.2.4. Market size and forecast, by end user
6.2.5.1. U.S.
6.2.5.2. U.S. Market size and forecast, by application
6.2.5.3. Market size and forecast, by end user
6.2.5.4. Canada
6.2.5.5. Canada Market size and forecast, by application
6.2.5.6. Canada Market size and forecast, by end user
6.2.5.7. Mexico
6.2.5.8. Mexico Market size and forecast, by application
6.2.5.9. Mexico Market size and forecast, by end user
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Europe Market size and forecast, by country
6.3.3. Market size and forecast, by application
6.3.4. Europe Market size and forecast, by end user
6.3.4.1. Germany
6.3.4.2. Germany Market size and forecast, by application
6.3.4.3. Germany Market size and forecast, by end user
6.3.4.4. France
6.3.4.5. France Market size and forecast, by application
6.3.4.6. France Market size and forecast, by end user
6.3.4.7. UK
6.3.4.8. UK Market size and forecast, by application
6.3.4.9. UK Market size and forecast, by end user
6.3.4.10. Italy
6.3.4.11. Italy Market size and forecast, by application
6.3.4.12. Market size and forecast, by end user
6.3.4.13. Spain
6.3.4.14. Spain Market size and forecast, by application
6.3.4.15. Spain Market size and forecast, by end user
6.3.4.16. Rest of Europe
6.3.4.17. Rest of Europe Market size and forecast, by application
6.3.4.18. Rest of Europe Market size and forecast, by end user
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by country
Market size and forecast, by application
6.4.3. Market size and forecast, by end user
6.4.3.1. Japan
6.4.3.2. Japan Market size and forecast, by application
6.4.3.3. Japan Market size and forecast, by end user
6.4.3.4. China
6.4.3.5. China Market size and forecast, by application
6.4.3.6. China Market size and forecast, by end user
6.4.3.7. Australia
6.4.3.8. Australia Market size and forecast, by application
6.4.3.9. Australia Market size and forecast, by end user
6.4.3.10. India
6.4.3.11. India Market size and forecast, by application
6.4.3.12. India Market size and forecast, by end user
6.4.3.13. South Korea
6.4.3.14. South Korea Market size and forecast, by application
6.4.3.15. South Korea Market size and forecast, by end user
6.4.3.16. Rest of Asia-Pacific
6.4.3.17. Rest of Asia-Pacific Market size and forecast, by application
6.4.3.18. Rest of Asia-Pacific Market size and forecast, by end user
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by country
6.5.3. Market size and forecast, by application
6.5.4. Market size and forecast, by end user
6.5.4.1. Brazil
6.5.4.2. Brazil Market size and forecast, by application
6.5.4.3. Brazil Market size and forecast, by end user
6.5.4.4. Saudi Arabia
6.5.4.5. Saudi Arabia Market size and forecast, by application
6.5.4.6. Saudi Arabia Market size and forecast, by end user
6.5.4.7. South Africa
6.5.4.8. South Africa Market size and forecast, by application
6.5.4.9. South Africa Market size and forecast, by end user
6.5.4.10. Rest of LAMEA
6.5.4.11. Rest of LAMEA Market size and forecast, by application
6.5.4.12. Rest of LAMEA Market size and forecast, by end user
CHAPTER 7: COMPANY PROFILES:
7.1. ATLAS BIOLOGICALS
7.1.1. Company overview
7.1.2. Company snapshot
7.2. BIO-TECHNE (ATLANTA BIOLOGICS)
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. Danaher (cytiva)
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. HIMEDIA LABORATORIES PVT., LTD
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.5. Merck KGAA (SIGMA ALDRICH)
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. PAN-BIOTECH
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.7. ROCKY MOUNTAIN BIOLOGICALS (RMBIO)
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.8. SARTORIUS (Biological industries)
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. SERA SCANDIA A/S (BIOWEST)
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.10. THERMO FISHER SCIENTIFIC INC.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
7.11. Other Key Player Profile
7.11.1. Key player snapshot
List of Tables
TABLE 01. FETAL BOVINE SERUM MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 02. FETAL BOVINE SERUM MARKET FOR BIOPHARMACEUTICALS, BY REGION 2020–2030($MILLION)
TABLE 03. FETAL BOVINE SERUM MARKET FOR HUMAN AND ANIMAL VACCINE PRODUCTION, BY REGION 2020–2030 ($MILLION)
TABLE 04. FETAL BOVINE SERUM MARKET FOR OTHERS, BY REGION 2020–2030 ($MILLION)
TABLE 05. GLOBAL FETAL BOVINE SERUM MARKET, BY END USER 2020–2030 ($MILLION)
TABLE 06. FETAL BOVINE SERUM MARKET FOR BIOTECHNOLOGY & PHARMACEUTICAL INDUSTRIES, BY REGION 2020–2030 ($MILLION)
TABLE 07. FETAL BOVINE SERUM MARKET REVENUE FOR ACADEMIC INSTITUTES, BY REGION 2020–2030 ($MILLION)
TABLE 08. FETAL BOVINE SERUM MARKET REVENUE FOR OTHERS, BY REGION 2020–2030($MILLION)
TABLE 09. GLOBAL FETAL BOVINE SERUM MARKET, BY REGION 2020–2030 ($MILLION)
TABLE 10. NORTH AMERICA FETAL BOVINE SERUM MARKET REVENUE, BY COUNTRY 2020–2030 ($MILLION)
TABLE 11. NORTH AMERICA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 12. NORTH AMERICA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 13. U.S. FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 14. U.S. FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 15. CANADA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 16. CANADA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 17. MEXICO FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 18. MEXICO FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 19. EUROPE FETAL BOVINE SERUM MARKET REVENUE, BY COUNTRY 2020–2030 ($MILLION)
TABLE 20. EUROPE FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 21. EUROPE FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 22. GERMANY FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 23. GERMANY FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 24. FRANCE FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 25. FRANCE FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 26. UK FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 27. UK FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 28. ITALY FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 29. ITALY FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 30. SPAIN FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 31. SPAIN FETAL BOVINE SERUM MARKET REVENUE, BY END USER 202-2030($MILLION)
TABLE 32. REST OF EUROPE FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030($MILLION)
TABLE 33. REST OF EUROPE FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030($MILLION)
TABLE 34. ASIA-PACIFIC FETAL BOVINE SERUM MARKET REVENUE, BY COUNTRY 2020–2030 ($MILLION)
TABLE 35. ASIA-PACIFIC FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030($MILLION)
TABLE 36. ASIA-PACIFIC FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 37. JAPAN FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 38. JAPAN FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 39. CHINA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 40. CHINA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 41. AUSTRALIA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 42. AUSTRALIA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 43. INDIA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 44. INDIA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 45. SOUTH KOREA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 46. SOUTH KOREA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 47. REST OF ASIA-PACIFIC FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 48. REST OF ASIA-PACIFIC FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 49. LAMEA FETAL BOVINE SERUM MARKET REVENUE, BY COUNTRY 2020–2030 ($MILLION)
TABLE 50. LAMEA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 51. LAMEA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 52. BRAZIL FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 53. BRAZIL FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 54. SAUDI ARABIA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 55. SAUDI ARABIA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 56. SOUTH AFRICA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 57. SOUTH AFRICA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 58. REST OF LAMEA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2020–2030 ($MILLION)
TABLE 59. REST OF LAMEA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2020–2030 ($MILLION)
TABLE 60. ATLAS: COMPANY SNAPSHOT
TABLE 61. BIO-TECHNE COMPANY SNAPSHOT
TABLE 62. BIO-TECHNE OPERATING SEGMENTS
TABLE 63. BIO-TECHNE: PRODUCT PORTFOLIO
TABLE 64. DANAHER: COMPANY SNAPSHOT
TABLE 65. DANAHER: OPERATING SEGMENTS
TABLE 66. DANAHER HEALTHCARE: PRODUCT PORTFOLIO
TABLE 67. HIMEDIA: COMPANY SNAPSHOT
TABLE 68. HIMEDIA: OPERATING SEGMENTS
TABLE 69. HI MEDIA: PRODUCT PORTFOLIO
TABLE 70. MERCK: COMPANY SNAPSHOT
TABLE 71. MERCK: OPERATING SEGMENTS
TABLE 72. MERCK: PRODUCT PORTFOLIO
TABLE 73. PAN: COMPANY SNAPSHOT
TABLE 74. PAN: OPERATING SEGMENTS
TABLE 75. PAN: PRODUCT PORTFOLIO
TABLE 76. RMBIO: COMPANY SNAPSHOT
TABLE 77. RMBIO: OPERATING SEGMENTS
TABLE 78. RMBIO: PRODUCT PORTFOLIO
TABLE 79. SARTORIUS: COMPANY SNAPSHOT
TABLE 80. SARTORIUS: OPERATING SEGMENTS
TABLE 81. SARTORIUS: PRODUCT PORTFOLIO
TABLE 82. SERA SCANDIA: COMPANY SNAPSHOT
TABLE 83. BIOWEST: OPERATING SEGMENTS
TABLE 84. SERA SCANDIA: PRODUCT PORTFOLIO
TABLE 85. THERMO FISHER: COMPANY SNAPSHOT
TABLE 86. THERMO FISHER: OPERATING SEGMENTS
TABLE 87. THERMO FISHER: OPERATING SEGMENTS
List of Figures
FIGURE 01. KEY MARKET SEGMENTS
FIGURE 02. MARKET EVOLUTION/INDUSTRIES ROADMAP
FIGURE 03. VALUE CHAIN ANALYSIS
FIGURE 04. TOP IMPACTING FACTORS
FIGURE 05. TOP INVESTMENT POCKETS
FIGURE 06. MARKET PLAYER POSITIONING, 2020
FIGURE 07. FETAL BLOOD COLLECTION PROCESS
FIGURE 09. COMPARATIVE SHARE ANALYSIS OF FETAL BOVINE SERUM MARKET FOR BIOPHARMACEUTICALS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF FETAL BOVINE SERUM MARKET FOR HUMAN AND ANIMAL VACCINE PRODUCTION, BY COUNTRY, 2020 & 2030 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF FETAL BOVINE SERUM MARKET FOR OTHER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF FETAL BOVINE SERUM MARKET FOR BIOTECHNOLOGY & PHARMACEUTICAL INDUSTRIES, BY COUNTRY, 2020 & 2030(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF FETAL BOVINE SERUM MARKET FOR ACADEMIC INSTITUTESS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF FETAL BOVINE SERUM MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15. BIO-TECHNE NET SALES, 2018–2020 ($MILLION)
FIGURE 17. BIO-TECHNE REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 18. BIO-TECHNE REVENUE SHARE, BY REGION 2020 (%)
FIGURE 19. DANAHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 20. DANAHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 21. DANAHER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 22. MERCK: REVENUE, 2018–2020 ($MILLION)
FIGURE 24. MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 26. MERCK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 28. SARORIUS: NET SALES, 2018–2020 ($MILLION)
FIGURE 29. SARTORIOUS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30. SARTORIUS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 31. THERMO FISHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 32. THERMO FISHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 33. THERMO FISHER: REVENUE SHARE BY REGION, 2020 (%)

Companies Mentioned

  • Danaher (Cytiva)
  • Merck KGaA (Sigma Aldrich)
  • HiMedia Laboratories Pvt.Ltd
  • Bio-Techne
  • Sera Scandia (Biowest)
  • Sartorius (Biological Industries)
  • Atlas Biologicals
  • Rocky Mountain Biologicals
  • PAN-Biotech
  • Thermo Fisher Scientific Inc

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...